二肽基肽酶4抑制剂在糖尿病肾病患者中的应用和疗效评价

Application and efficacy evaluation of dipeptidyl peptidase 4 inhibitor in patients with diabetic nephropathy

糖尿病(diabetes mellitus)的发病人数持续增加,高达40%的糖尿病患者可出现肾脏损伤,即糖尿病肾病(diabetic nephropathy,DN)。二肽基肽酶(dipeptidyl peptidase,DPP)4抑制剂作为一种新型降糖药物,不仅可有效控制血糖,还能延缓DN的发生、发展。本文通过分析DPP4抑制剂在DN患者中的应用,从控制血糖、改善肾脏损伤和保护心血管几个方面进行阐述,为探讨DPP4抑制剂的作用和延缓DN的发生、发展提供新的思路。

The incidence of diabetes mellitus (DM) continues to rise,up to 40% of DM patients will appear kidney damage,namely diabetic nephropathy (DN).Dipeptidyl peptidase-4 (DPP4) inhibitor,as a new hypoglycemic drug,can not only effectively control blood glucose,but also delay the occurrence and development of DN.Through analyzing the application of DPP4 inhibitors in DN patients,this paper expounded from the aspects of blood glucose control,improvement of kidney injury and cardiovascular protection,so as to provide new ideas for exploring the role of DPP4 inhibitors and delaying the occurrence and development of DN.